| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
56.72
|
|
2
|
Projections of global mortality and burden of disease from 2002 to 2030.
|
PLoS Med
|
2006
|
49.95
|
|
3
|
Standardisation of spirometry.
|
Eur Respir J
|
2005
|
48.20
|
|
4
|
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
|
Am J Respir Crit Care Med
|
1998
|
10.05
|
|
5
|
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.
|
Thorax
|
1999
|
8.63
|
|
6
|
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
|
Ann Intern Med
|
1987
|
8.41
|
|
7
|
Development and first validation of the COPD Assessment Test.
|
Eur Respir J
|
2009
|
8.06
|
|
8
|
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.
|
Hepatology
|
2002
|
7.53
|
|
9
|
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations.
|
Eur Respir J
|
2012
|
7.18
|
|
10
|
Chronic obstructive pulmonary disease: current burden and future projections.
|
Eur Respir J
|
2006
|
6.34
|
|
11
|
St. George's Respiratory Questionnaire: MCID.
|
COPD
|
2005
|
3.99
|
|
12
|
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
|
Am J Respir Crit Care Med
|
2009
|
3.61
|
|
13
|
Minimum clinically important difference for the COPD Assessment Test: a prospective analysis.
|
Lancet Respir Med
|
2014
|
2.69
|
|
14
|
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
|
Lancet
|
2016
|
2.19
|
|
15
|
Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.
|
Aliment Pharmacol Ther
|
2011
|
1.97
|
|
16
|
The local side effects of inhaled corticosteroids: current understanding and review of the literature.
|
Chest
|
2004
|
1.76
|
|
17
|
Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores.
|
BMC Pulm Med
|
2011
|
1.54
|
|
18
|
Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
|
Respir Med
|
2011
|
1.14
|
|
19
|
Measuring the effects of COPD on the patient.
|
Respir Med
|
2005
|
1.13
|
|
20
|
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
|
Respir Med
|
2011
|
1.05
|
|
21
|
Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.
|
Respir Med
|
2014
|
1.03
|
|
22
|
Inhalational and topical steroids, and oral candidosis: a mini review.
|
Oral Dis
|
2001
|
0.95
|
|
23
|
Acute bronchodilator responsiveness in subjects with and without airflow obstruction in five Latin American cities: the PLATINO study.
|
Pulm Pharmacol Ther
|
2009
|
0.82
|
|
24
|
FULFIL Trial: Once-Daily Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
|
Am J Respir Crit Care Med
|
2017
|
0.80
|
|
25
|
Standardisation of lung function testing: the authors' replies to readers' comments.
|
Eur Respir J
|
2010
|
0.77
|
|
26
|
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
|
Lancet
|
2017
|
0.76
|
|
27
|
Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire.
|
Chronic Obstr Pulm Dis
|
2017
|
0.75
|